Skip to main content
Premium Trial:

Request an Annual Quote

Advent Venture Partners Start Life Science Fund with $118M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – London-based venture capital firm Advent Venture Partners today announced the final close of a £75 million ($118 million) life science VC fund.

The fund, called Advent Life Sciences, is the company's first that focuses on the life sciences and will invest mostly in early- and mid-stage companies in the UK, Europe, and the US. Advent Life Sciences will provide funding to companies with a first- or best-in-class approach in a variety of sectors, including diagnostics, medical technology, new drug discovery, and enabling technologies, it said in a statement.

Participants in the round include the UK Future Technologies Fund, managed by the European Investment Fund. Among the companies that Advent Venture Partners has invested in or helped found are molecular diagnostics firm Biocartis, Avila Therapeutics, and Cellnovo.

Filed under

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.